-

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets

UTRECHT, The Netherlands--(BUSINESS WIRE)--At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell biology and pathobiology research. It complements Bruker’s Avance Neo 1.1 GHz and 1.2 GHz NMR systems with two-story 2 Kelvin magnets, which typically are used at shared national NMR facilities, such as the 1.2 GHz NMR at the Dutch Ultra-high Field Magnetic Resonance Consortium, operating at Utrecht University.

A first new 1.0 GHz NMR order comes from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan. The RIKEN team under Dr. Ichio Shimada will use GHz NMR to study dynamical structures of biomolecules in solution and to investigate the relationships between dynamical structures and biological function or pathobiology.

Bruker also confirms two 1.0 GHz NMR orders from major research centers and universities in Bilbao and Barcelona, both in Spain, for clinical and biological research:

Professor Óscar Millet, Principal Investigator of the Precision Medicine and Metabolism Lab at CIC bioGUNE stated: “The Ascend Evo 1.0 GHz will advance our research in clinical metabolomics. This novel magnet provides highest-resolution NMR to investigate the molecular patterns and mechanism of action of prevalent and rare diseases in precision medicine, all in a single-story lab and with a smaller footprint.”

Professor Miquel Pons Valles, Group Leader of the BioNMR Group at Universitat de Barcelona and his team use biophysical methods, especially NMR, as well as chemical biology, molecular biology, and computations to study proteins in regulatory processes, where dynamics is essential for function. The Ascend Evo 1.0 GHz will also advance their research on intrinsically disordered proteins (IDPs).

The recently introduced, compact Ascend Evo 1.0 GHz NMR magnet has significantly reduced footprint, weight, and ceiling height requirements to fit into most single-story laboratories. Along with a 65% reduction in helium consumption, this provides more structural biology principal investigators, individual universities and research centers, as well as advanced biopharma companies access to the sensitivity and resolution of GHz NMR in order to enable new research capabilities.

Another innovation is Bruker’s new Heliosmart Recovery, a compact and easy-to-site system that collects helium boil-off from NMR magnets. Helium gas is stored in high-pressure cylinders, which can be used by cryogen suppliers for reliquification. The Heliosmart Recovery system can collect the steady-state boil-off of several NMR magnets in parallel with typical recovery rates of 80% – 85%.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "We are excited to announce the three new GHz orders, which will incorporate our innovative, single-story Ascend Evo 1.0 GHz magnet. This technological marvel brings the power of GHz NMR to more laboratories due to its smaller footprint, reduced maintenance requirements and lower Helium consumption.”

Please join Bruker at Euromar at our booth for interaction with our NMR and EPR teams.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 7243 769 5500
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 7243 769 5500
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...

Bruker Announces Quarterly Preferred Stock Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202...
Back to Newsroom